title: Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention.
abstract: The percutaneous coronary intervention (PCI) procedure has become one of the pivotal options in the treatment of coronary artery disease (CAD). Although the PCI procedure has rapidly developed in China, some concerns including in-stent restenosis and dissatisfactory long-term prognosis remain unsolved. Large-scale randomized controlled clinical trials indicate that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can reduce all-cause mortality and recurrent cardiac events in patients with CAD. ACEIs/ARBs are recommended as a fundamental treatment in the secondary prevention of CAD and reduce in-stent restenosis after PCI. This review focuses on the role of ACEIs/ARBs in improving long-term prognosis and reducing in-stent restenosis.
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
authors.forename: Zhuang
authors.initials: Z
authors.lastname: Xiao-Dong
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Fei-Fei
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhan-Peng
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
authors.forename: Liao
authors.initials: L
authors.lastname: Xin-Xue
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan Er Road, Guangzhou 510080, P. R. China duzhimin@mail.sysu.edu.cn.
authors.forename: Du
authors.initials: D
authors.lastname: Zhi-Min
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D015607:Stents / Q000009:adverse effects*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors
keywords: angiotensin II receptor blockers; angiotensin-converting enzyme inhibitors; in-stent restenosis; percutaneous coronary intervention; prognosis